Astec Lifesciences: September ’22 Results Update
Moneylife Digital Team 23 November 2022
In Q2FY22-23, Astec Lifesciences (Astec) nearly doubled its sales y-o-y (year-on-year) to Rs200 crore. The robust top-line performance was driven by higher sales realisation and volumes in exports and higher realisations in the domestic market. Also, sales deferral of previous quarter, which was 15%-20% of Q1FY22-23 revenue, was included in Q2FY22-23 revenue. Along with increase in...
Archived Premium Content
This article is outside your subscription period. You can buy this article individually.
SINGLE ARTICLE
Rs 50-Rs 100 + GST
Access will be given ONLY to this article.
 
Get access to complete archives
Rs 5000 + GST
 
 
Already a subscriber ? Log in
Free Helpline
Legal Credit
Feedback